Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Usage Information

Central Role of High Density Lipoprotein in Plasma Free Cholesterol Metabolism
Charles C. Schwartz, Z. Reno Vlahcevic, Mones Berman, John G. Meadows, Richard M. Nisman, Leon Swell
Charles C. Schwartz, Z. Reno Vlahcevic, Mones Berman, John G. Meadows, Richard M. Nisman, Leon Swell
View: Text | PDF
Research Article

Central Role of High Density Lipoprotein in Plasma Free Cholesterol Metabolism

  • Text
  • PDF
Abstract

This study was designed to provide direct information on the in vivo metabolism in man of free (unesterified) cholesterol in the major lipoprotein classes. Five human subjects were administered one or two (simultaneous) of the following; [2-14C] mevalonic acid, high density lipoprotein (HDL)-free [14C] cholesterol, low density lipoprotein (LDL)-free [14C] cholesterol, and very low density lipoprotein (VLDL)-free [3H]cholesterol. Blood was then obtained at frequent intervals for at least 9 h, and the α(HDL) and β(LDL + VLDL) lipoproteins were quickly separated by heparin-manganese precipitation to prevent ex vivo exchange of free cholesterol. After the administration of [14C]mevalonic acid the specific activity (disintegrations per minute/micromole) of free cholesterol in the α- and β-lipoproteins increased for 3 h. During this period the α-free cholesterol specific activity was higher than the β specific activity. After administration of VLDL and LDL labeled with free cholesterol, the α-free cholesterol specific activity reached a peak value within 20 min, at which time it was considerably lower than the β-free cholesterol specific activity. When HDL labeled with free cholesterol was administered, a precursor product relationship was observed between the α-free cholesterol (precursor) and β-free cholesterol (product) specific activities.

Authors

Charles C. Schwartz, Z. Reno Vlahcevic, Mones Berman, John G. Meadows, Richard M. Nisman, Leon Swell

×

Usage data is cumulative from November 2025 through November 2026.

Usage JCI PMC
Text version 392 17
PDF 217 6
Scanned page 1,132 3
Citation downloads 293 0
Totals 2,034 26
Total Views 2,060
(Click and drag on plot area to zoom in. Click legend items above to toggle)

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts